Article
Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
2023-10-23
Abstract excerpt
<h4>Background: </h4> Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are considered the standard first-line therapy for treatment-naive patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have sensitizing EGFR mutations. Currently, there are three generations of EGFR-TKIs available for the treatment of EGFR mutation-positive NSCLC. However, the optimal sequence of ad...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a1cd0a86-ac43-5bd1-a9e2-d0fd534739b6
- DOI
- 10.21203/rs.3.rs-3449456/v1
